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reverse the inhibitory function of anti-apoptotic Bcl-2 proteins. 4 Dependency on Bcl-2 family protein expression requests BH3 profiling to efficiently stratify patients potentially benefiting from ABT-199 therapy. 5 Most often, Mcl-1 is considered a main resistance factor 2 and recently a first class of selective Mcl-1 inhibitors was characterized. 6 As an alternative to functional inhibitors, we previously described proteasome-dependent downregulation of Mcl-1 expression 7, 8 by cardiac glycoside UNBS1450. [8] [9] [10] We hypothesize here that a combination of UNBS1450 with a BH3 mimetic would affect acute myeloid leukemia (AML) subtypes especially 'addicted' to Mcl-1. To provide a targeted therapeutic approach, we describe the synergistic antileukemic effect of ABT-199 with UNBS1450 in cell lines, colony formation assays, zebrafish xenografts and validate results in primary cells from 23 de novo AML patients. Figure 1a shows the expression pattern of major anti-apoptotic Bcl-2 proteins of selected AML cell lines suitable for the assessment of single/combinational strategies. First, we assessed the sensitivity of these cells against ABT-199, ABT-263 and UNBS1450 as a single agent, by determining inhibitory concentration (IC 50 ) values after 24 h (Figure 1b) . A multiple linear regression for each drug on the three proteins (Figure 1c) Figure 1) . A-1210477 primed TF-1 cells (highly co-expressing Bcl-xL/Mcl-1) to apoptosis only when combined with ABT-263. We then replaced A-1210477 by UNBS1450. In U937 cells, we documented a strong synergistic effect when UNBS1450 was combined with both ABTs (confidence interval = 0.14-0.18; Figure 1d As platelets were strongly affected by ABT-263, 2,3 we tested different concentrations of UNBS1450 alone or in combination with ABT-199 without impacting the viability of leukocytedepleted platelets pool from healthy donors. AML. Bcl-2 protein expression patterns, especially Mcl-1, could become an essential biomarker allowing AML patient stratification and response prediction. Results also prompt to explore both role and/or origin of the different Mcl-1 isoforms in drug response, a novel and emerging topic. A few studies focus on the modulatory roles of short isoforms and the actual biological functions of the 32 KDa Mcl-1 short isoform were recently investigated. 13, 14 Moreover, from a mechanistic point of view, UNBS1450-induced degradation of Mcl-1 occurs via proteasome-dependent, noxa-independent degradation of preexisting Mcl-1 rather than by a transcriptional modulation of Mcl-1 expression. 8 Further studies are required to validate subtype dependency on Bcl-2 protein expression more likely to benefit from a combination treatment. Recent application of BH3 profiling on patient samples allows establishing Bcl-2 dependency and predicting ABT response profile. 15 The same approach can be applied to predict patients responsive to combination treatments.
So far, our analysis was carried out on de novo AML. We will extend our investigations to relapsed forms. Moreover, the patient panel tested so far does not allow correlations with specific factors including age, sex or cytogenetic mutations. An exploratory study to correlate specific mutations to drug response indicates that FLT3-ITD mutation has not the same effect for all treatments as opposed to FLT3-WT (Supplementary Figure 6) : it decreases susceptibility to ABT-199 (−16%) and combination treatments (−12%), whereas increasing susceptibility to UNBS1450 (+20%). Even though none of these effects is significant in our limited panel, however, this preliminary evidence encourages further studies on effects of UNBS1450 alone or in combination with ABTs on FLT3-ITD AML patients' subgroups.
Importantly, we observed here that subtoxic single treatments by ABT compounds do not change anti-apoptotic Bcl-2 protein expression. Moreover, UNBS1450 downregulates Mcl-1 without a compensatory overexpression of other Bcl-2 family proteins (Figure 1d) Western blot analysis of anti-apoptotic Bcl-2 protein expression. Synergy was estimated by using the 'response additivity' approach. Corresponding combinational index (CI) of significant interactions were computed. Statistical analyses were performed in GraphPad Prism (GraphPad Software Inc., La Jolla, CA, USA). Significance is *P o0.05; **P o0.01; ***Po0.001; ****P o0.0001 (two-way analysis of variance; repeated measures; post hoc analyses Dunnett; Sidak).
